EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 507 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive... April 8, 2024 Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... March 27, 2024 Patient Guide in Testicular Cancer Now Available Also in German January 14, 2026 Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC April 19, 2022 Load more HOT NEWS Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... New on NCI’s Websites for November 2024 How keeping active during cancer treatment has helped Mary and Keith Cancer Prevention Message Is Key for HPV Vaccination Discussions with Parents
